CD34–L-selectin adhesion interface (CD34–SELL interface)

CD34 is a transmembrane phosphoglycoprotein and sialomucin primarily expressed on hematopoietic stem cells and vascular endothelial cells, where it serves as a critical scaffold for carbohydrate ligands that bind to L-selectin (CD62L) [1]. The CD34–L-selectin adhesion interface is formed by the interaction between the N-terminal lectin domain of L-selectin and specific O-linked glycans, such as sialyl Lewis X (sLeX), presented on the CD34 protein backbone [2]. This interaction is a fundamental component of the leukocyte adhesion cascade, facilitating the initial tethering and rolling of lymphocytes on high endothelial venules (HEVs) within secondary lymphoid organs [3]. In pathological states, this interface is implicated in the recruitment of inflammatory cells to sites of chronic injury and the homing of malignant cells in certain types of leukemia [4]. Therapeutic targeting of this interface typically involves small-molecule glycomimetics or monoclonal antibodies designed to competitively inhibit the selectin-binding site, thereby disrupting cell-cell adhesion and reducing inflammatory infiltration or metastatic spread [5].

Other names

CD34-L-selectin interactionCD34-CD62L adhesion interfaceSialomucin-selectin binding siteCD34-SELL complex

Competitive inhibition of the selectin lectin domain to prevent binding of sialylated carbohydrate ligands on CD34